Related Experiment Videos
Methods for Tumor Targeting with Salmonella typhimurium A1-R
1AntiCancer Inc. and Department of Surgery, University of California - San Diego, San Diego, CA, USA. all@anticancer.com.
Abstract:
Salmonella typhimurium A1-R (S. typhimurium A1-R) has shown great preclinical promise as a broad-based anti-cancer therapeutic (please see Chapter 1 ). The present chapter describes materials and methods for the preclinical study of S. typhimurium A1-R in clinically-relevant mouse models. Establishment of orthotopic metastatic mouse models of the major cancer types is described, as well as other useful models, for efficacy studies of S. typhimurium A1-R or other tumor-targeting bacteria, as well. Imaging methods are described to visualize GFP-labeled S. typhimurium A1-R, as well as GFP- and/or RFP-labeled cancer cells in vitro and in vivo, which S. typhimurium A1-R targets. The mouse models include metastasis to major organs that are life-threatening to cancer patients including the liver, lung, bone, and brain and how to target these metastases with S. typhimurium A1-R. Various routes of administration of S. typhimurium A1-R are described with the advantages and disadvantages of each. Basic experiments to determine toxic effects of S. typhimurium A1-R are also described. Also described are methodologies for combining S. typhimurium A1-R and chemotherapy. The testing of S. typhimurium A1-R on patient tumors in patient-derived orthotopic xenograft (PDOX) mouse models is also described. The major methodologies described in this chapter should be translatable for clinical studies.
Insights
Salmonella typhimurium A1-R is a promising anti-cancer therapy. This chapter details preclinical methods using mouse models to study its efficacy against various cancers, including metastasis.
Area of Science:
- Oncology
- Microbiology
- Preclinical Research
Background:
- Salmonella typhimurium A1-R demonstrates significant preclinical potential as a broad-spectrum anti-cancer therapeutic.
- Effective preclinical evaluation requires robust and clinically relevant models.
Purpose of the Study:
- To describe materials and methods for preclinical studies of S. typhimurium A1-R.
- To establish and utilize clinically relevant mouse models for efficacy and safety assessments.
- To provide methodologies translatable for future clinical studies.
Main Methods:
- Establishment of orthotopic metastatic mouse models for major cancer types.
- In vitro and in vivo imaging of GFP-labeled S. typhimurium A1-R and fluorescently labeled cancer cells.
- Evaluation of S. typhimurium A1-R in models of metastasis to liver, lung, bone, and brain.
- Assessment of various administration routes, toxicity, and combination therapies with chemotherapy.
- Testing in patient-derived orthotopic xenograft (PDOX) models.
Main Results:
- Detailed methodologies for preclinical evaluation of S. typhimurium A1-R are presented.
- The described models allow for visualization and quantification of bacterial targeting and anti-cancer effects.
- The study outlines approaches for assessing safety and efficacy across various cancer types and metastatic sites.
Conclusions:
- The methodologies described provide a framework for the preclinical assessment of S. typhimurium A1-R.
- These methods are designed to be translatable to clinical settings, facilitating the advancement of this therapeutic.
- The study supports the continued development of S. typhimurium A1-R as a novel anti-cancer agent.